Table 1.
Effects of STE on the inflammatory and oxidative-related mediators.
| Mediators | Groups | ||||
|---|---|---|---|---|---|
| NC | MC | SASP | L-STE | H-STE | |
| MPO (U/mgprot) | 0.07 ± 0.03 c | 0.23 ± 0.10 a | 0.10 ± 0.05 bc | 0.15 ± 0.07 b | 0.12 ± 0.06 bc |
| IL-6 (pg/mL) | 2.31 ± 0.22 c | 3.30 ± 0.16 a | 2.62 ± 0.39 bc | 2.76 ± 0.40 b | 2.64 ± 0.30 bc |
| IL-1β (pg/mL) | 2.62 ± 0.14 c | 3.70 ± 0.37 a | 2.84 ± 0.51 bc | 2.74 ± 0.44 bc | 2.36 ± 0.27 b |
| TNF-α (pg/mL) | 30.44 ± 0.86 b | 38.49 ± 6.15 a | 29.29 ± 4.46 b | 28.31 ± 4.40 b | 25.97 ± 5.60 b |
| LPS (pg/mL) | 2.90 ± 0.44 c | 4.33 ± 0.36 a | 3.28 ± 0.30 bc | 3.31 ± 0.14 bc | 3.37 ± 0.38 b |
| IL-10 (pg/mL) | 20.34 ± 3.17 a | 14.16 ± 1.47 b | 17.45 ± 3.93 ab | 17.37 ± 3.42 ab | 18.20 ± 3.54 a |
| TGF-β (pg/mL) | 47.66 ± 1.36 a | 41.41 ± 1.60 c | 43.44 ± 1.81 bc | 44.94 ± 1.96 b | 45.14 ± 2.05 b |
| SOD (U/mgprot) | 843.42 ± 58.82 a | 640.74 ± 55.09 c | 737.87 ± 46.00 b | 738.59 ± 37.61 b | 767.09 ± 72.61 b |
| GSH (mg/gprot) | 3.90 ± 0.70 a | 1.26 ± 0.32 d | 1.71 ± 0.64 cd | 2.37 ± 0.96 bc | 2.98 ± 0.82 ab |
| MDA (nmol/mgprot) | 1.00 ± 0.14 d | 1.91 ± 0.22 a | 1.55 ± 0.22 b | 1.31 ± 0.26 bc | 1.25 ± 0.23 cd |
Abbreviations: MPO, myeloperoxidase; IL-6, interleukin-6; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; LPS, lipopolysaccharide; IL-10, interleukin-10; TGF-β, transforming growth factor-β; SOD, superoxide dismutase; GSH, glutathione; MDA, malondialdehyde; NC, normal control group; MC, DSS-induced UC model group; SASP, suffasalarin intervention group at the dose of 100 mg/kg; L-STE, STE intervention group at the dose of 100 mg/kg; H-STE, STE intervention group at the dose of 400 mg/kg. Data are expressed as the mean ± the SD (n = 10) and analyzed by one-way ANOVA followed by Duncan’s multiple comparisons test. The different superscript lowercase letters in the same column indicate statistical significance (p < 0.05).